Although the mechanism behind bevacizumab-induced HTN is unknown, it is theorized to be from the inhibition of the vascular endothelial growth factor (VEGF) signaling pathway, leading to increased systemic vascular resistance [45]. The gene discussed is VEGFA; the disease is hypertensive disorder.